{"url_path":"/sec/clrb/8-k/2026-05-08/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-057460-index.html","accession_number":"0001104659-26-057460","cik":"0001279704","ticker":"CLRB","issuer_name":"Cellectar Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-057460-index.html","primary_entity_key":"0001279704","primary_entity_name":"Cellectar Biosciences, Inc."},"word_count":241,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.**\n\n \n\n**Exhibit Number**\n \n**Description**\n\n[4.1](tm2613728d1_ex4-1.htm)\n \n[Form of Pre-Funded Common Stock Purchase Warrant](tm2613728d1_ex4-1.htm)\n\n[4.2](tm2613728d1_ex4-2.htm)\n \n[Form of Series A Common Stock Purchase Warrant](tm2613728d1_ex4-2.htm)\n\n[4.3](tm2613728d1_ex4-3.htm)\n \n[Form of Series B Common Stock Purchase Warrant](tm2613728d1_ex4-3.htm)\n\n[4.4](tm2613728d1_ex4-4.htm)\n \n[Form of Series C Common Stock Purchase Warrant](tm2613728d1_ex4-4.htm)\n\n[4.5](tm2613728d1_ex4-5.htm)\n \n[Form of Placement Agent Warrant](tm2613728d1_ex4-5.htm)\n\n[5.1](tm2613728d1_ex5-1.htm)\n \n[Opinion of Sidley Austin LLP](tm2613728d1_ex5-1.htm)\n\n[10.1](tm2613728d1_ex10-1.htm)\n \n[Form of Securities Purchase Agreement, dated May 4, 2026, by and among the Company and the institutional investors identified on the signatures pages thereto](tm2613728d1_ex10-1.htm)\n\n[10.2](tm2613728d1_ex10-2.htm)\n \n[Form of Securities Purchase Agreement, dated May 4, 2026, by and among the Company and the members of management identified on the signatures pages thereto](tm2613728d1_ex10-2.htm)\n\n[10.3](tm2613728d1_ex10-3.htm)\n \n[Form of Registration Rights Agreement, dated May 4, 2026, by and among the Company and the investors identified on the signature pages thereto](tm2613728d1_ex10-3.htm)\n\n[10.4](tm2613728d1_ex10-4.htm)\n \n[Form of Placement Agency Agreement, dated May 4, 2026, by and between the Company and Ladenburg Thalmann & Co. Inc.](tm2613728d1_ex10-4.htm)\n\n[10.5](tm2613728d1_ex10-5.htm)\n \n[Letter Agreement, dated May 4, 2026, by and between the Company and Nantahala Capital Management, LLC](tm2613728d1_ex10-5.htm)\n\n[23.1](tm2613728d1_ex5-1.htm)\n \n[Consent of Sidley Austin LLP (included in Exhibit 5.1)](tm2613728d1_ex5-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**CELLECTAR BIOSCIENCES, INC.**\n\n \n \n \n\nDate: May 8, 2026\nBy:\n*/s/ Chad J. Kolean*\n\n \nName:\nChad J. Kolean\n\n \nTitle:\nChief Financial Officer"}